Heska (NASDAQ:HSKA) was upgraded by stock analysts at TheStreet from a “d+” rating to a “c-” rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.
HSKA has been the topic of a number of other research reports. ValuEngine upgraded shares of Heska from a “hold” rating to a “buy” rating in a report on Thursday, October 1st. Piper Sandler upgraded shares of Heska from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $87.00 to $110.00 in a report on Wednesday, August 5th. Zacks Investment Research lowered shares of Heska from a “hold” rating to a “sell” rating in a report on Friday, October 23rd. Raymond James upgraded shares of Heska from a “market perform” rating to an “outperform” rating and set a $125.00 target price on the stock in a report on Wednesday, October 21st. Finally, Alliance Global Partners increased their price objective on shares of Heska from $90.00 to $116.50 and gave the company a “buy” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $99.42.
Shares of NASDAQ HSKA opened at $111.99 on Tuesday. The firm’s 50-day moving average price is $102.69 and its 200-day moving average price is $91.74. Heska has a 1-year low of $50.00 and a 1-year high of $122.19. The firm has a market capitalization of $1.06 billion, a P/E ratio of -66.27 and a beta of 1.68. The company has a current ratio of 4.82, a quick ratio of 3.58 and a debt-to-equity ratio of 0.18.
Heska (NASDAQ:HSKA) last posted its earnings results on Tuesday, August 4th. The medical research company reported ($0.72) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.29). Heska had a negative return on equity of 1.57% and a negative net margin of 9.57%. The business had revenue of $45.71 million during the quarter, compared to analyst estimates of $41.94 million. Equities research analysts forecast that Heska will post -0.59 EPS for the current year.
In other news, CEO Kevin S. Wilson sold 13,421 shares of the stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $110.28, for a total transaction of $1,480,067.88. Following the completion of the transaction, the chief executive officer now directly owns 72,955 shares of the company’s stock, valued at approximately $8,045,477.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Nancy Wisnewski sold 1,050 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $103.87, for a total transaction of $109,063.50. Following the transaction, the chief operating officer now directly owns 49,124 shares of the company’s stock, valued at $5,102,509.88. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,776 shares of company stock valued at $2,913,217. Company insiders own 11.70% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Advisor Group Holdings Inc. grew its position in shares of Heska by 95.6% during the 2nd quarter. Advisor Group Holdings Inc. now owns 401 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 196 shares during the period. Mutual of America Capital Management LLC grew its position in shares of Heska by 34.9% during the 2nd quarter. Mutual of America Capital Management LLC now owns 410 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 106 shares during the period. AQR Capital Management LLC bought a new position in Heska in the 2nd quarter worth approximately $206,000. Louisiana State Employees Retirement System bought a new position in Heska in the 2nd quarter worth approximately $218,000. Finally, State of Tennessee Treasury Department boosted its holdings in Heska by 11.5% in the 1st quarter. State of Tennessee Treasury Department now owns 2,377 shares of the medical research company’s stock worth $131,000 after buying an additional 245 shares during the period. 96.19% of the stock is owned by hedge funds and other institutional investors.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.